Johnson & Johnson (NYSE:JNJ) Shares Sold by W.H. Cornerstone Investments Inc.

W.H. Cornerstone Investments Inc. trimmed its holdings in Johnson & Johnson (NYSE:JNJ) by 5.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 7,910 shares of the company’s stock after selling 464 shares during the period. Johnson & Johnson accounts for about 0.8% of W.H. Cornerstone Investments Inc.’s investment portfolio, making the stock its 28th largest position. W.H. Cornerstone Investments Inc.’s holdings in Johnson & Johnson were worth $1,144,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in JNJ. IFS Advisors LLC grew its stake in Johnson & Johnson by 138.9% in the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock valued at $25,000 after acquiring an additional 100 shares during the last quarter. Highline Wealth Partners LLC purchased a new position in Johnson & Johnson in the 3rd quarter valued at about $31,000. Bay Harbor Wealth Management LLC purchased a new position in Johnson & Johnson in the 4th quarter valued at about $32,000. RPg Family Wealth Advisory LLC purchased a new position in Johnson & Johnson in the 3rd quarter valued at about $35,000. Finally, Mowery & Schoenfeld Wealth Management LLC lifted its holdings in Johnson & Johnson by 58.7% in the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock valued at $40,000 after purchasing an additional 91 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Mark A. Weinberger acquired 1,000 shares of the company’s stock in a transaction dated Thursday, December 12th. The shares were bought at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the purchase, the director now directly owns 1,000 shares of the company’s stock, valued at approximately $147,220. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Down 0.7 %

Shares of NYSE:JNJ opened at $156.20 on Tuesday. The company has a market capitalization of $376.08 billion, a price-to-earnings ratio of 23.49, a price-to-earnings-growth ratio of 2.46 and a beta of 0.52. The company has a 50 day moving average of $147.87 and a two-hundred day moving average of $155.95. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $168.85. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The company had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The business’s quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter last year, the firm posted $2.29 earnings per share. As a group, analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.18%. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on JNJ shares. Royal Bank of Canada restated an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a report on Thursday, January 23rd. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 25th. Bank of America reduced their target price on shares of Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating on the stock in a report on Thursday, January 23rd. Argus upgraded shares of Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. Finally, Barclays upped their price target on shares of Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a research report on Tuesday, January 28th. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $170.67.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.